Ovarian Cancer Low Risk Study

Should women be screened for ovarian cancer?

We hope to answer this question with the Ovarian Cancer Low Risk Study. About 25,000 women in the U. S. are diagnosed with ovarian cancer each year. Most don’t have any symptoms until the disease is advanced. Currently, MD Anderson does not recommend routine screening for ovarian cancer.

Are there ovarian cancer screening tests available?

Currently, there are no effective tests to detect ovarian cancer at its earliest stages, but if ovarian cancer is found early, the chances of cure increase dramatically. MD Anderson researchers hope this study will result in more effective ovarian cancer screening methods.

What is the purpose of this study?

MD Anderson researchers are evaluating a blood (CA-125) and urine test that may be helpful in the early detection of ovarian cancer in healthy, post-menopausal women.

Here’s how it works.

We:

  • conduct a telephone interview with you
  • perform a blood test (annually or quarterly)
  • request that you complete a medical history questionnaire
  • perform a transvaginal ultrasound (for some, but not all participants)

Am I eligible?

You’re eligible to participate if you:

  • are between the ages of 50 and 74
  • are post-menopausal (no period for one year or longer)
  • have not received cancer treatment for at least 12 months

What are the benefits of participating?

Participants will:

  • receive ovarian cancer screening tests at no cost
  • contribute valuable information to medical research which may benefit future generations

How do I find out more or enroll?

Currently our study is available in Iowa, New Jersey, Rhode Island and Texas. Participants will need to travel to one of these locations below for the blood  test and transvaginal ultrasound if needed. We will continue to add more sites, so please refer back to this webpage for updates.

Please call or email one of the contacts below and ask how you can become a participant in the Low Risk Ovarian Study ID01-022.

Iowa

John Stoddard Cancer Center/Unity Point Health
1221 Pleasant St.
Suite 450
Des Moines, IA 50309
Contact:  Pati Berger, RN, BSN, OCN
pati.berger@unitypoint.org
Office:  515-241-8704
Fax:      515-241-4633

New Jersey

Carol G. Simon Cancer Center / Atlantic Health
Morristown Memorial Hospital
100 Madison Avenue
Morristown, NJ 07962
Contact:  Maria Bell
Maria.Bell@atlantichealth.org
Office:  973-219-1264
Fax:      973-290-7327

Rhode Island

Woman & Infants Hospital
45 Willard Avenue
Providence, RI 02905
Contact: Cindy Brizard
cbrizard@WIHRI.org
Office:  401-274-1122  x48190
Fax:      401-276-7805

Texas

The University of Texas MD Anderson Cancer Center
1400 Pressler St.
Unit 1439
Houston, Texas 77030
Contact:  Alexis Perez, CMA
amperez@mdanderson.org
Office:  713-563-6728
Fax:      713-563-5620

Women’s Hospital of Texas (OGA)
7900 Fannin St.
Suite 4000
Houston, TX 77054
Contact:  Veronica Solano, CPT
vsolano@mdanderson.org
Office:  713-512-7789
Fax:      713-512-7669

UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX  75390
Contact:  Isabel Villalobos, MS
Isabel.Villalobos@UTSouthwestern.edu
Office:  214-648-7010
Fax:      214-648-7024
Contact:  Tiffany Thomas
Tiffany.Thomas@UTSouthwestern.edu
Office:   214-648-7094
Fax:       214-648-7024

Who are the specialists involved in this study?

Karen H. Lu, MD, study chair for the Low Risk Ovarian Cancer Study

Will my information be kept confidential?

All information that you provide, as well as your blood sample results, will be completely confidential. No one outside this study may have access to your information without your permission.